Health ❯ Healthcare ❯ Patient Outcomes

Adverse Events

Clinical Study Results Mortality Rates Major Bleeding Long-term Follow-up Death Investigations Cardiopulmonary Decompensation Safety Profiles Treatment Tolerability Bleeding Complications Bleeding Risk

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

The ACC 2026 analysis signals earlier, more aggressive LDL cholesterol lowering could reshape primary prevention for patients with diabetes.

HI-PEITHO Finds Catheter Ultrasound Thrombolysis Halves 30-Day Events in Intermediate-Risk PE

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Repatha Cuts First Major Cardiac Events by 25% in At-Risk Adults in AHA Trial

TCT 2025: Stent‑Sparing Balloons Match DES at One Year as Lower‑Cost Alternatives Rival IVL

ESC Trials Recast Antiplatelet Strategies After PCI and CABG

Eli Lilly’s Lepodisiran Achieves 94% Reduction in Genetic Heart Disease Risk Factor in Phase 2 Trial

Eli Lilly's Zepbound Shows Promise in Reducing Heart Failure Risks